Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer

Exclusion Criteria

• •Is pregnant or breastfeeding.
• •Is a woman of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards.
• •Is a man of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards.
• •Has a history of brain metastases, unless adequately treated and without radiologic evidence of progressive disease for at least 3 months after completion of therapy.
• •Has a known active infection.